Bank of America Corp DE Sells 137,220 Shares of Annexon, Inc. (NASDAQ:ANNX)

Bank of America Corp DE cut its position in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 82.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 29,940 shares of the company's stock after selling 137,220 shares during the quarter. Bank of America Corp DE's holdings in Annexon were worth $154,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ANNX. BNP Paribas Financial Markets purchased a new stake in Annexon during the fourth quarter worth about $59,000. CANADA LIFE ASSURANCE Co bought a new position in shares of Annexon during the 4th quarter valued at approximately $77,000. E Fund Management Co. Ltd. increased its stake in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock worth $79,000 after purchasing an additional 4,086 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Annexon in the 4th quarter worth approximately $98,000. Finally, Arizona State Retirement System bought a new stake in shares of Annexon in the 4th quarter worth approximately $102,000.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ANNX. Needham & Company LLC reduced their price objective on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright decreased their price objective on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Annexon Stock Up 2.4%

Shares of ANNX stock traded up $0.06 on Friday, reaching $2.40. The company's stock had a trading volume of 632,994 shares, compared to its average volume of 1,488,365. The company has a market capitalization of $262.76 million, a P/E ratio of -2.03 and a beta of 1.26. Annexon, Inc. has a 12-month low of $1.29 and a 12-month high of $7.85. The stock's 50 day simple moving average is $2.00 and its 200-day simple moving average is $3.03.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Research analysts expect that Annexon, Inc. will post -0.96 EPS for the current year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.